Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug c… Read more
Nuvation Bio Inc (NUVB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.162x
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has a cash flow conversion efficiency ratio of -0.162x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.89 Million) by net assets ($325.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nuvation Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nuvation Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nuvation Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvation Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Odfjell Drilling Ltd
OL:ODL
|
0.063x |
|
Goosehead Insurance Inc
NASDAQ:GSHD
|
-0.142x |
|
Juventus Football Club S.p.A
PINK:JVTSF
|
1.738x |
|
EVEREST MED.LTD DL-0001
F:6HN
|
N/A |
|
Air France-KLM SA
PINK:AFRAF
|
1.455x |
|
Guangdong Orient Zirconic Ind Sci & Tech Co Ltd
SHE:002167
|
0.092x |
|
Yellow Cake plc
OTCQX:YLLXF
|
-0.001x |
|
The Wendy’s Co
NASDAQ:WEN
|
0.590x |
Annual Cash Flow Conversion Efficiency for Nuvation Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $463.79 Million | $-130.41 Million | -0.281x | -150.23% |
| 2023-12-31 | $605.12 Million | $-68.00 Million | -0.112x | +23.41% |
| 2022-12-31 | $655.08 Million | $-96.11 Million | -0.147x | -60.50% |
| 2021-12-31 | $746.00 Million | $-68.19 Million | -0.091x | +46.18% |
| 2020-12-31 | $215.08 Million | $-36.53 Million | -0.170x | +18.15% |
| 2019-12-31 | $117.75 Million | $-24.43 Million | -0.207x | -125.06% |
| 2018-12-31 | $-744.00K | $-616.00K | 0.828x | -- |